Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-1167 and Famitinib in Neoadjuvant gBRCAm HER2- Breast Cancer
NCT06516289Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of M9466 in breast cancer, sponsored by Fudan University. Started Sep 2024; status: recruiting.
02
Drugs
M9466
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06516289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516289.